ATHN 2: Factor Switching Study



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any
Updated:1/2/2019
Start Date:September 2015
End Date:January 2022
Contact:Hilary Markoe
Email:hsummermarkoe@athn.org
Phone:800 360 2846

Use our guide to learn which trials are right for you!

A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products

This is a longitudinal, observational study of patients with Hemophilia A or B who are
planning to switch to a newly approved coagulation factor replacement product, or who have
recently switched factor products. The study will follow each patient for up to 1 year.
Patients will be recruited at Hemophilia Treatment Centers (HTC) which are ATHN-affiliates.
The primary outcome being studied is the development of inhibitor (i.e., antibodies to
factor) at 1 year or 50 exposure days, whichever comes first.

The study will be conducted at approximately 30 HTCs, with a planned enrollment of 600
patients.The entire study duration is projected to be approximately 6 years.

In addition, optional substudies will be included for some products, as "Product-Specific
Modules". These will be questionnaires to collect data for subjects receiving selected Factor
products. For example, subjects receiving Kovaltry will be approached to participate in the
'Kovaltry Product-Specific Module'; subjects receiving Adynovate will be approached to
participate in the 'Adynovate Product-Specific Module'. Questions will be related to product
use, perceptions of product use, and other post-marketing consumer data.

This non-interventional, minimal risk cohort study will enroll patients with Hemophilia A or
B who are planning or have recently switched to a new Factor product. The study will have 2
Arms, prospective and retrospective. The Prospective Arm will enroll patients who plan to
switch to a new factor. The Retrospective Arm will enroll patients who have recently switched
to a new factor (within the previous 50 weeks). Patient will be seen at baseline and for up
to 4 additional visits, and quarterly follow-up by phone. Required study visits will be
planned to coincide with routine follow-up visits whenever possible.

Please note that Factor Replacement Products are not being provided by the study.

The primary objective is to assess and characterize the rate of inhibitor development within
one (1) year or fifty (50) exposure days, whichever is first, after switching clotting factor
replacement products in previously treated patients (PTPs) with hemophilia A or B.

Data collected will include eligibility, demographics, medical history, hemophilia history
(clotting history, product history, genotype and family history), inhibitor history,
co-morbidities at baseline (i.e., HIV, Hepatitis C.), detailed clotting factor replacement
product(s) usage and switching plan, and reasons for switching factor products. Also targeted
physical exams will be performed at baseline and during follow-up, and targeted concomitant
medication data will be collected. Data collection will also include patient-reported
outcome(s) after 1 year, bleeding events, surgeries, laboratory Inhibitor testing and details
regarding testing methodology, pharmacokinetic (PK) data (if known), new diagnoses, and
co-morbidities (targeted), Safety/Adverse Events using European Union Hemophilia Safety
Surveillance (EUHASS) definitions.

This study will evolve to include any newly approved (since January 2013) factors as they
come to market. Cohorts will be defined by the brand/type of new clotting factor replacement
product approved after January 1, 2013. The current list of specific new Factor VIII
replacement products include Eloctate® (Bioverativ) and NovoEight® (NovoNordisk); Factor IX
replacement products include Alprolix® (Bioverativ), Rixubis® (Baxalta), and IXinity®
(Emergent Biosolutions). Others are both now available and imminent and include: Adynovate®,
Idelvion®, Afstyla®, Kovaltry® and Jivi®.

The over-arching rationale for this protocol is that a pragmatic study which is consistent
with real world practices across a wide range of patients that is not principally tied to a
particular manufacturer or product may be of great advantage to the entire hemophilia
community.

Study Duration

- Subjects on prophylaxis will be followed on study for up to 1 year. Each subject will be
seen during a study visit or contacted by telephone at least once every 3 months (i.e.,
quarterly). Patients may participate for multiple 'cycles', if they switch factor
products more than once while the study is actively recruiting.

Treatment regimen will be at the discretion of the subject's hemophilia caregivers. No
treatment is being provided by the study.

- Substudies A number of substudies are planned with pharmaceutical sponsors to collect
information from patients about their products' use. Participation in these optional
substudies (product-specific modules) will be planned to coincide with study visits.
These modules will collect information from subjects about their perception and use of
factor use/treatment, physical activity levels and other general health questions. These
data will be collected via questionnaire, primarily via phone.

Concomitant and Excluded Therapies

- Immune tolerance therapy is excluded on study. This includes immunosuppressive
treatments used to eradicate inhibitors. Steroid treatments for allergic disorders and
asthma, are allowed.

Data Collection System

- All data collected will be entered into electronic case report forms (eCRFs) within the
secure ATHN Study Manager system. Subject Identifiers (IDs) will be generated in
Clinical Manager.

- Reimbursement will be managed by each participating HTC. Most study centers will
reimburse study subjects for travel and parking, but this varies by center.

Inclusion Criteria

- Moderate or Severe Congenital Hemophilia A or B (FVIII or FIX clotting activity less
than or equal to 5% of normal).

- Able to give informed consent (by patient or parent/authorized guardian).

- Previously treated with plasma-derived or recombinant clotting factor replacement
products with at least 50 exposure days (as assessed either from direct clinical
records in children under age 5, or by clinical history of dosing in older patients).
For Arm B being enrolled retrospectively, this previous treatment must be prior to
product switch under study.

- Planning to switch, or recently switched within the previous 50 weeks, to a new brand
or type of replacement factor VIII or IX, FDA approved after January 1, 2013.

- Arm B only: Negative inhibitor screen within the last 6 months prior to switching.

Note: History of prior transient inhibitor or inhibitor eradicated by immune tolerance
induction (ITI) are eligible.

Exclusion Criteria

- Presence of any known bleeding disorder other than hemophilia A or B (i.e., patients
with concurrent hemophilia and a second hemostatic defect are NOT eligible). Low Von
Willebrand Factor (VWF) without VWF diagnosis are not excluded.

- Presence of an active inhibitor >0.6 BU for factor VIII, > 0.4 BU for factor IX at the
time of eligibility assessment. Detection of such an inhibitor at the baseline visit
prior to dosing with the new product (Arm A), or after dosing with new factor dosing
(Arm B), would result in early termination without other study assessments.

- Currently undergoing ITI.

- Immunosuppressive therapy (cyclophosphamide, mycophenolate, IVIG) within 90 days and
Rituximab within 6 months; topical steroid treatments and short course steroids for
asthma or allergy allowed.

- Previous participation in Phase I, II or III interventional trials of the factor
product being switched to.
We found this trial at
27
sites
2401 Gillham Rd
Kansas City, Missouri 64108
(816) 234-3000
Principal Investigator: Brian Wicklund, MD
Phone: 816-302-6854
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Ulrike Reiss, MD
Phone: 901-595-6411
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Michael Recht, MD
Phone: 503-418-4495
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
Principal Investigator: Steven Pipe, MD
Phone: 734-936-5905
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Robert Sidonio, MD
Phone: 404-727-9698
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Michael Wang, MD
Phone: 303-724-0363
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 21205
Principal Investigator: Courtney Lawrence, MD
Phone: 410-614-0834
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
300 Longwood Avenue
Boston, Massachusetts 02115
Principal Investigator: Stacy Croteau, MD
Phone: 617-919-6407
?
mi
from
Boston, MA
Click here to add this to my saved trials
Dallas, Texas 75235
Phone: 214-456-2888
?
mi
from
Dallas, TX
Click here to add this to my saved trials
East Lansing, Michigan 48824
Principal Investigator: Roshni Kulkarni, MD
Phone: 517-353-9385
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
8326 Naab Road
Indianapolis, Indiana 46260
Principal Investigator: Amy Shapiro, MD
Phone: 317-871-0011
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Lebanon, New Hampshire 03756
Principal Investigator: Debra Ornstein, MD
Phone: 603-650-5486
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Milwaukee, Wisconsin 53233
Principal Investigator: Lynn Malec, MD
Phone: 414-257-2424
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
333 Cedar Street
New Haven, Connecticut 06520
Principal Investigator: Salley Pels, MD
Phone: 203-785-4011
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Principal Investigator: Tamuella Singleton, MD
Phone: 504-988-3596
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Catherine McGuinn, MD
Phone: 212-746-3403
?
mi
from
New York, NY
Click here to add this to my saved trials
Peoria, Illinois 61614
Principal Investigator: Michael Tarantino, MD
Phone: 309-692-5337
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Leslie Raffini, MD
Phone: 215-590-0431
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Adam Cuker, MD
Phone: 215-614-0506
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Margaret Ragni, MD
Phone: 412-209-7288
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, New York 14621
Principal Investigator: Peter Kouides, MD
Phone: 585-922-5006
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Saint Petersburg, Florida 33701
Principal Investigator: Irmel Ayala, MD
Phone: 727-767-4178
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
San Diego, California 92103
Principal Investigator: Annette Von Drygalski, MD
Phone: 858-657-6384
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Scarborough, Maine 04074
Principal Investigator: Eric Larsen, MD
Phone: 207-396-7312
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
921 Terry Avenue
Seattle, Washington 98104
Principal Investigator: Rebecca Kruse-Jarres, MD
Phone: 206-689-6539
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida
Principal Investigator: Erin Cockrell, DO
Phone: 813-870-0848
?
mi
from
Tampa, FL
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Michael Guerrera, MD
Phone: 202-476-3622
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials